Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma

Head and Neck

Volumn 33, Issue 9, 2011, Pages 1340-1345

  Fury, Matthew G ^a   Drobnjak, Marija ^a   Sima, Camelia S ^a   Asher, Marina ^a   Shah, Jatin ^a   Lee, Nancy ^a   Carlson, Diane ^a   Wendel, H Guido ^a   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

HPV; mTOR; p16; tissue microarray; tonsil

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P53; S6 KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TOBACCO DEPENDENCE; TONSIL CARCINOMA; TONSILLAR SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; SMOKING; TISSUE ARRAY ANALYSIS; TONSILLAR NEOPLASMS;

EID: 80051764841     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21621     Document Type: Article

References (42)

1. Engelman JA,. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
2. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13: 4964-4973. (Pubitemid 47502060)
3. Guertin DA, Sabatini DM,. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22. (Pubitemid 47001784)
4. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-313. (Pubitemid 351692089)
5. Vidal L, Gillison ML,. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008; 22: 1125-1142.
6. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420. (Pubitemid 351480511)
7. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL, and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
8. Gillison ML, Harris J, Westra W, et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Onco 2009; 27: 155 (suppl; abstr 6003).
9. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492. (Pubitemid 26170679)
10. Perez-Ordoñez B, Beauchemin M, Jordan RC,. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59: 445-453.
11. Fury MG, Pfister DG,. Head and neck squamous cell carcinoma. In:, Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB, editors. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders; 2008. pp 479-485.
12. Hafkamp HC, Mooren JJ, Claessen SM, et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol 2009; 22: 686-698.
13. Sellers WR, Kaelin WG Jr,. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 3301-3312. (Pubitemid 27485848)
14. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747. (Pubitemid 46622040)
15. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH,. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003; 9: 6469-6475. (Pubitemid 38031835)
16. Klussman JP, Gültekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-753. (Pubitemid 36237483)
17. Yarbrough WG, Whigham A, Brown B, Roach M, Slebos R,. Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69 (2 Suppl): S98-S101. (Pubitemid 47369377)
18. Mamane Y, Petroulakis E, Martineau Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007; 2: e242.
19. Rajaskhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC,. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003; 12: 889-901. (Pubitemid 37352782)
20. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337. (Pubitemid 38418805)
21. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237. (Pubitemid 350277750)
22. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J,. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999; 17: 2909-2914. (Pubitemid 29415252)
23. Nathan CO, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004; 10: 5820-5827. (Pubitemid 39180961)
24. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY,. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 2009; 8: 1463-1469.
25. Puig P, Capodieci P, Drobnjak M, et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res 2003; 9: 5642-5651. (Pubitemid 37499486)
26. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002; 33: 968-974. (Pubitemid 35215839)
27. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003; 107: 394-400. (Pubitemid 37266459)
28. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13: 748-753. (Pubitemid 46889749)
29. McBride SM, Perez DA, Polley MY, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 2010; 97: 33-40.
30. Mavrakis KJ, Zhu H, Silva RL, et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 2008; 22: 2178-2188.
31. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16: 88-98.
32. Girlando S, Slomp P, Caffo O, et al. p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. Virchows Arch 1999; 435: 559-565.
33. Capodanno A, Camerini A, Orlandini C, et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast cancer. Hum Pathol 2009; 40: 1408-1417.
34. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM,. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14: 366-369. (Pubitemid 351226102)
35. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720. (Pubitemid 30365531)
36. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058. (Pubitemid 41161231)
37. Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukarytotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007; 27: 7405-7413. (Pubitemid 350033648)
38. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation. Cell 2005; 120: 747-759. (Pubitemid 40568794)
39. Fury MG, Sherman E, Stambuk H, et al. Phase I study of everolimus (E; RAD001) + low dose weekly cisplatin (C) for patients with advanced solid tumors: preliminary results. J Clin Oncol 2009; 27 (suppl; abstr e14527).
40. Walsh D, Mohr I,. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev 2004; 18: 660-672. (Pubitemid 38489934)
41. Walsh D, Arias C, Perez C, et al. Eukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cells. Mol Cell Biol 2008; 28: 2648-2658. (Pubitemid 351542365)
42. Oh KJ, Kalinina A, Park NH, Bagchi S,. Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. J Virol 2006; 80: 7079-7088. (Pubitemid 44026426)